Close Menu

supply agreement

Integrated DNA Technologies said it will act as the primary supplier of next-generation sequencing oligo products for Clear Lab's NGS-based Clear Safety platform.

Agilent has agreed to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.

As part of the deal, which is worth at least $3 million for the first five years, Primerdesign will develop and supply 384-well plate molecular assay panels for Genesis.

The probes are for use in Cancer Genetics' FISH-based HPV-Associated Cancer Test, which measures genomic changes to help triage cervical cancer patients.

Public sector programs in some low- and middle-income countries will obtain access to Hologic's Panther system through a single, all-inclusive pricing structure.

Illumina has extended a supply agreement with Foundation until 2023 and developed an automated metagenomics workflow with PerkinElmer.

OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.

Sema4, spun out of Mount Sinai earlier this year, will standardize its two major labs on the Core Informatics Platform for Science as it looks to grow.

OraSure noted that the devices allow ambient temperature transportation and storage of a liquid sample to enable high throughput automation in a laboratory.

British genomics interpretation software vendor Congenica inked a deal with a Portuguese hospital to analyze whole-exome sequencing data for the In2Genome project.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.